Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors

被引:53
作者
Coban, C
Ishii, KJ
Gursel, M
Klinman, DM
Kumar, N
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Johns Hopkins Malaria Res Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
[2] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA
关键词
Plasmodium falciparum; oligonucleotides; dendritic cells;
D O I
10.1189/jlb.1104627
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
DNA vaccines, in general, have been found to be poorly immunogenic in nonhuman primates and humans as compared with mice. As the immunogenicity of DNA plasmids relies, to a large extent, on the presence of CpG motifs as built in adjuvants, we addressed the issue of poor immunogenicity by inserting recently identified CpG oligonucleotides (ODN) optimal for human (K-type or D-type CpG ODN) into the backbone of plasmid VR1020. We found that plasmid DNA containing K-type CpG motifs or D-type CpG motifs significantly enhanced the up-regulation of surface molecules and production of interleukin-6 from human peripheral blood mononuclear cells (PBMC) and stimulated monocytes to develop into functionally mature dendritic cells (DC) compared with unmodified plasmid. Monocyte maturation into DC was through plasmacytoid DC present in the culture. It is interesting that the K-type CpG motif-modified plasmid stimulated significant levels of interferon (IFN)-gamma and IFN-alpha from human PBMC. Immunization of mice with D-type CpG motif-modified plasmid, encoding Plasmodium falciparum surface protein 25, yielded enhanced antigen-specific antibodies. Taken together, these results suggest that insertion of immunomodulatory human CpG motifs into plasmid DNA can improve immunogenicity of DNA vaccines.
引用
收藏
页码:647 / 655
页数:9
相关论文
共 36 条
[21]  
Lobo CA, 1999, INFECT IMMUN, V67, P1688
[22]   An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi [J].
Luke, CJ ;
Carner, K ;
Liang, XW ;
Barbour, AG .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :91-97
[23]   Progress in DNA-based heterologous prime-boost immunization strategies for malaria [J].
Moore, AC ;
Hill, AVS .
IMMUNOLOGICAL REVIEWS, 2004, 199 (01) :126-143
[24]   Recent advances in the discovery and delivery of vaccine adjuvants [J].
O'Hagan, DT ;
Valiante, NM .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) :727-735
[25]   Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors [J].
Pontarollo, RA ;
Babiuk, LA ;
Hecker, R ;
Littel-van den Hurk, SV .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :2973-2981
[26]   Immunostimulatory DNA sequences necessary for effective intradermal gene immunization [J].
Sato, Y ;
Roman, M ;
Tighe, H ;
Lee, D ;
Corr, M ;
Nguyen, MD ;
Silverman, GJ ;
Lotz, M ;
Carson, DA ;
Raz, E .
SCIENCE, 1996, 273 (5273) :352-354
[27]   PROTECTION AGAINST MALARIA BY IMMUNIZATION WITH PLASMID DNA ENCODING CIRCUMSPOROZOITE PROTEIN [J].
SEDEGAH, M ;
HEDSTROM, R ;
HOBART, P ;
HOFFMAN, SL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) :9866-9870
[28]  
Shoda LKM, 2001, J LEUKOCYTE BIOL, V70, P103
[29]   Vaccination with plasmid DNA activates dendritic cells via toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice [J].
Spies, B ;
Hochrein, H ;
Vabulas, M ;
Huster, K ;
Busch, DH ;
Schmitz, F ;
Heit, A ;
Wagner, H .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :5908-5912
[30]   Cutting edge: Role of toll-like receptor 9 in CpG DNA-induced activation of human cells [J].
Takeshita, F ;
Leifer, CA ;
Gursel, I ;
Ishii, KJ ;
Takeshita, S ;
Gursel, M ;
Klinman, DM .
JOURNAL OF IMMUNOLOGY, 2001, 167 (07) :3555-3558